Scarica l'app Stockscreener
6.86
104.78%
3.51
Pre-mercato:
6.85
-0.01
-0.15%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACCD Giù?
Forum
Previsione
Accolade Inc Borsa (ACCD) Ultime notizie
Accolade (NASDAQ:ACCD) Rating Lowered to Hold at Leerink Partnrs - MarketBeat
Transcarent to acquire health advocacy and primary care company Accolade for $621m - MSN
Stifel Nicolaus Reaffirms Hold Rating for Accolade (NASDAQ:ACCD) - MarketBeat
Estimate suggests Accolade may outperform with a potential 320% upside - Dataconomy
Accolade, with 500 employees in Montco, to be acquired in $621M deal - The Business Journals
Accolade (NASDAQ:ACCD) Receives Market Perform Rating from Raymond James - MarketBeat
Accolade to be acquired by Transcarent for $7.03 per share in cash - Yahoo Finance
How Accolade stock pulled off a 105% jump - Dataconomy
Stifel downgrades Accolade stock as competing bids deemed unlikely - Investing.com
Stifel Downgrades Accolade Inc. (ACCD) to Hold - StreetInsider.com
Raymond James Downgrades Accolade Inc. (ACCD) to Market Perform - StreetInsider.com
Earnings Scheduled For January 9, 2025 - Benzinga
Accolade Gets a Do-Over With Transcarent’s $621M Acquisition - MedCity News
Seattle health care company to go private in $621 million acquisition deal - The Business Journals
ACCOLADE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Accolade, Inc.ACCD - Business Wire
Truist maintains Buy on Accolade stock, reiterates $7.50 target By Investing.com - Investing.com South Africa
Accolade's (ACCD) "Hold" Rating Reiterated at Needham & Company LLC - MarketBeat
What Transcarent's $621M Acquisition of Accolade Means for Behavioral Health - Behavioral Health Business
Why Is Accolade Stock Trading Over 100% On Tuesday? - Benzinga
What's Going On With Accolade Stock Wednesday? - Benzinga
Truist maintains Buy on Accolade stock, reiterates $7.50 target - Investing.com India
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Me - GuruFocus.com
Accolade (NASDAQ:ACCD) Receives Market Perform Rating from Leerink Partners - MarketBeat
Wilson Sonsini, Cooley Lead $621M Take-Private Of Accolade - Law360
Geode Capital Management Increases Stake in Accolade, Inc. – Market - HPBL
Accolade Inc. (ACCD): Q3 2025 Earnings Preview and Stock Outlook – Market - HPBL
Halper Sadeh LLC Investigates Accolade, Inc. Sale to Transcarent for Fairness to Shareholders - HPBL
Transcarent to acquire fellow health benefits navigator Accolade for $621M - Healthcare Dive
Accolade (ACCD) Stock Update: Analyst Ratings and Market Performance – Market - HPBL
Truist Securities Reiterates Buy Rating on Accolade Inc. (ACCD) - StreetInsider.com
Shareholder Alert: Ademi LLP Investigates Whether Accolade, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Accolade, Inc.ACCD - Longview News-Journal
Accolade (NASDAQ:ACCD) Shares Gap UpWhat's Next? - MarketBeat
Healthcare M&A: Transcarent paying $621M to acquire Seattle-based health benefits firm Accolade - GeekWire
Transcarent to acquire Accolade for $621 million creating benefits tech giant - STAT
ACCD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Accolade, Inc. Is Fair to Shareholders - Business Wire
Accolade Acquired by Transcarent in Strategic Merger - TipRanks
Accolade stock soars on $621M Transcarent acquisition deal - Investing.com
Transcarent to acquire health benefits platform Accolade in $621M deal - Fierce healthcare
Accolade (ACCD) to Resume Trading at 9 am - StreetInsider.com
Transcarent To Acquire Accolade - GlobeNewswire
Transcarent To Acquire Accolade (ACCD) for $7.03 per share - StreetInsider.com
Accolade Inc (ACCD) Q3 2025 Earnings Report Preview: What To Exp - GuruFocus.com
Accolade Inc (ACCD) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Transcarent, Inc. agreed to acquire Accolade, Inc. from AH Parallel Fund IV, L.P. and Andreessen Horowitz Fund IV, L.P. managed by Andreessen Horowitz LLC and others. - Marketscreener.com
Accolade’s chief accounting officer sells shares worth $1,785 By Investing.com - Investing.com Nigeria
AcCOLADE EVP general counsel sells shares worth $1,338 - Investing.com India
Accolade's chief accounting officer sells shares worth $1,785 - Investing.com
AcCOLADE EVP general counsel sells shares worth $1,338 By Investing.com - Investing.com Australia
Accolade's chief accounting officer sells shares worth $1,785 By Investing.com - Investing.com Australia
Newport News-based ivWatch receives accolades for life-saving technology - The Virginian-Pilot
Accolade, Inc. (NASDAQ:ACCD) Receives $8.96 Average Price Target from Brokerages - MarketBeat
Accolade CEO Rajeev Singh sells shares worth $1,307 By Investing.com - Investing.com Australia
Accolade president Robert Cavanaugh sells $535 in stock transactions By Investing.com - Investing.com South Africa
AcCOLADE CFO Stephen Barnes sells $422 in stock By Investing.com - Investing.com South Africa
Accolade president Robert Cavanaugh sells $535 in stock transactions - Investing.com
Accolade CEO Rajeev Singh sells shares worth $1,307 - Investing.com India
NTUC LearningHub Pte Ltd receives accolade at TDM Travel Trade Excellence Awards 2024 – Asia - Travel Daily
Breaking Down Accolade: 8 Analysts Share Their Views - Benzinga
Accolade (NASDAQ:ACCD) Price Target Cut to $5.00 by Analysts at Morgan Stanley - MarketBeat
0.33%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):